샘플 요청 목록

 카트 문의
시장보고서
상품코드
1779897

세계의 시클로옥시게나아제 1 저해제 시장

Cyclooxygenase 1 Inhibitors
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 367 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 시클로옥시게나아제 1 저해제 시장은 2030년까지 1,022억 달러에 도달

2024년에 720억 달러로 추정되는 세계의 시클로옥시게나아제 1 저해제 시장은 2024-2030년에 CAGR 6.0%로 성장하며, 2030년에는 1,022억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 선택적 COX-1 저해제는 CAGR 7.4%를 기록하며, 분석 기간 종료까지 567억 달러에 달할 것으로 예상됩니다. 비선택적 COX-1 저해제 부문의 성장률은 분석 기간 중 CAGR 4.5%로 추정됩니다.

미국 시장은 196억 달러로 추정, 중국은 CAGR 9.7%로 성장할 것으로 예측

미국의 시클로옥시게나아제 1 저해제 시장은 2024년에 196억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 211억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 9.7%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.9%와 6.0%로 예측됩니다. 유럽에서는 독일이 CAGR 3.9%로 성장할 것으로 예측됩니다.

시클로옥시게나아제-1(COX-1) 저해제 세계 시장 - 주요 동향과 시장 성장 촉진요인 정리

COX-1 억제제가 항염증 치료제로 주목받는 이유는?

시클로옥시게나아제-1(COX-1) 억제제는 프로스타글란딘 합성을 조절하는 COX-1 효소를 표적으로 하여 통증 관리 및 항염증 치료에 중요한 역할을 합니다. 이 억제제는 염증이 중요한 역할을 하는 관절염, 심혈관계 질환, 위궤양 등의 치료에 널리 사용되고 있습니다. 염증 경로를 선택적으로 차단하는 COX-2 억제제와 달리 COX-1 억제제는 유익한 프로스타글란딘과 유해한 프로스타글란딘에 모두 작용하므로 위장 합병증을 피하기 위해 신중한 투약과 모니터링이 필요합니다.

만성 염증성 질환의 유병률 증가는 세계 인구의 고령화와 함께 COX-1 억제제에 대한 수요를 촉진하고 있습니다. 또한 혈소판 응집을 방지하는 COX-1 억제제의 역할은 심혈관 질환 관리, 특히 항응고 요법을 필요로 하는 환자들에게 필수적인 역할을 하고 있습니다. COX-1 억제제 시장은 연구자들이 안전성과 유효성을 높이기 위해 새로운 제형과 전달 방법을 모색함에 따라 의약품과 일반의약품(OTC) 통증 완화 분야에서 안정적인 성장세를 보이고 있습니다.

COX-1 억제제 연구의 최신 발전은 무엇인가?

차세대 COX-1 억제제 개발은 선택성 향상, 소화기 부작용 감소, 치료 효과 강화에 초점을 맞추었습니다. 최근에는 항염증 효과를 유지하면서 궤양 형성을 최소화하는 위장 보호 작용을 하는 COX-1 억제제의 제형이 개발되었습니다. 또한 COX-1 억제제의 생체 이용률과 표적 작용을 개선하기 위해 나노입자 기반의 약물전달 시스템이 연구되고 있습니다.

COX-1 억제제와 양성자 펌프 억제제(PPI) 또는 위장 보호제를 병용하여 부작용을 줄이는 병용요법도 중요한 혁신입니다. AI를 활용한 신약개발 방법도 안전성 프로파일을 개선한 새로운 COX-1 억제제 후보물질 발굴에 중요한 역할을 하고 있습니다. 또한 대체 항염증 경로에 대한 연구는 치료 옵션을 넓혀 COX-1 억제제 유도체 개발에 새로운 기회를 제공합니다.

시장 동향과 규제 정책은 COX-1 억제제 사용을 어떻게 형성하고 있는가?

COX-1 억제제를 포함한 비스테로이드성 항염증약(NSAIDs)를 규제하는 프레임워크는 시장 역학에 영향을 미치고 있습니다. 소화관 출혈, 심혈관계 위험과 같은 장기적인 부작용에 대한 우려로 인해 보건 당국은 표시 요건과 사용 가이드라인을 엄격하게 적용하고 있습니다. 또한 맞춤형 의료로의 전환은 유전적 소인과 위험 요인을 고려한 환자별 항염증 치료법 개발을 촉진하고 있습니다.

시장 동향은 특히 국소적 통증 완화를 위한 국소 및 경피적 COX-1 억제제에 대한 수요가 증가하고 있음을 보여줍니다. 아세트아미노펜과 아스피린을 함유한 진통제를 포함한 OTC 제제의 등장으로 소비자의 접근성이 확대되고 있습니다. 또한 기존의 비스테로이드성 항염증약(NSAIDs)를 대체할 수 있는 보다 안전한 약물을 찾는 연구자들 사이에서 식물 유래 또는 합성 COX-1 억제제에 대한 연구가 활발히 진행되고 있습니다.

COX-1 억제제 시장의 성장을 이끄는 요인은 무엇인가?

COX-1 억제제 시장 성장의 원동력은 염증성 질환의 유병률 증가, 약물전달 시스템의 발전, 효과적인 통증 관리 솔루션에 대한 소비자 수요 증가 등입니다. 표적 항염증 치료의 제약 연구가 확대됨에 따라 안전성 프로파일이 개선된 혁신적인 COX-1 억제제가 개발되고 있습니다.

최종 용도 확대도 중요한 원동력이 되고 있으며, 수술 후 통증 관리, 심혈관 질환 예방, 신경염증성 질환 등으로 용도가 확대되고 있습니다. 또한 동물 의료에서 COX-1 억제제의 사용 증가도 시장 성장에 기여하고 있습니다. 또한 제약회사와 연구기관의 공동연구는 차세대 COX-1 억제제 개발을 가속화하고 있으며, 항염증약 치료의 지속적인 발전을 보장하고 있습니다.

부문

유형(선택적 COX-1저해제, 비선택적 COX-1저해제), 용도(염증성 질환 용도, 소화기계 독성 용도, 암 화학 예방 용도, 기타 용도), 유통 채널(병원 약국 유통 채널, 온라인 약국 유통 채널, 소매 약국 유통 채널)

조사 대상 기업의 예

  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals plc
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.(now part of Viatris Inc.)
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.07

Global Cyclooxygenase 1 Inhibitors Market to Reach US$102.2 Billion by 2030

The global market for Cyclooxygenase 1 Inhibitors estimated at US$72.0 Billion in the year 2024, is expected to reach US$102.2 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Selective COX-1 Inhibitor, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$56.7 Billion by the end of the analysis period. Growth in the Non-Selective COX-1 Inhibitor segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$19.6 Billion While China is Forecast to Grow at 9.7% CAGR

The Cyclooxygenase 1 Inhibitors market in the U.S. is estimated at US$19.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$21.1 Billion by the year 2030 trailing a CAGR of 9.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

Global Cyclooxygenase-1 (COX-1) Inhibitors Market - Key Trends & Growth Drivers Summarized

Why Are COX-1 Inhibitors Gaining Attention in Anti-Inflammatory Therapy?

Cyclooxygenase-1 (COX-1) inhibitors play a crucial role in pain management and anti-inflammatory therapy by targeting the COX-1 enzyme, which regulates prostaglandin synthesis. These inhibitors are widely used in treating conditions such as arthritis, cardiovascular diseases, and gastric ulcers, where inflammation plays a critical role. Unlike COX-2 inhibitors, which selectively block inflammation pathways, COX-1 inhibitors affect both beneficial and harmful prostaglandins, necessitating careful dosing and monitoring to avoid gastrointestinal complications.

The increasing prevalence of chronic inflammatory diseases, coupled with the aging global population, has fueled demand for COX-1 inhibitors. Additionally, their role in preventing platelet aggregation has made them essential in cardiovascular disease management, particularly in patients requiring anticoagulant therapy. As researchers explore novel formulations and delivery methods to enhance safety and efficacy, the COX-1 inhibitor market is witnessing steady growth in both pharmaceutical and over-the-counter (OTC) pain relief segments.

What Are the Latest Advancements in COX-1 Inhibitor Research?

The development of next-generation COX-1 inhibitors is focused on improving selectivity, reducing gastrointestinal side effects, and enhancing therapeutic effectiveness. Recent advancements include the formulation of gastroprotective COX-1 inhibitors that minimize ulcer formation while maintaining anti-inflammatory benefits. Additionally, nanoparticle-based drug delivery systems are being explored to improve bioavailability and targeted action of COX-1 inhibitors.

Another key innovation is the combination therapy approach, where COX-1 inhibitors are paired with proton pump inhibitors (PPIs) or gastroprotective agents to reduce adverse effects. AI-driven drug discovery methods are also playing a crucial role in identifying new COX-1 inhibitor candidates with improved safety profiles. Additionally, research into alternative anti-inflammatory pathways is expanding therapeutic options, providing new opportunities for the development of COX-1 inhibitor derivatives.

How Are Market Trends and Regulatory Policies Shaping COX-1 Inhibitor Use?

Regulatory frameworks governing nonsteroidal anti-inflammatory drugs (NSAIDs), including COX-1 inhibitors, have influenced market dynamics. Concerns over long-term side effects, such as gastrointestinal bleeding and cardiovascular risks, have prompted health agencies to enforce stricter labeling requirements and usage guidelines. Additionally, the shift toward personalized medicine has encouraged the development of patient-specific anti-inflammatory treatments that consider genetic predisposition and risk factors.

Market trends indicate a growing demand for topical and transdermal COX-1 inhibitors, particularly for localized pain relief applications. The rise of OTC formulations, including combination pain relievers with acetaminophen or aspirin, has expanded consumer accessibility. Additionally, the exploration of plant-derived and synthetic COX-1 inhibitors is gaining traction as researchers seek safer alternatives to traditional NSAIDs.

What Is Driving the Growth of the COX-1 Inhibitor Market?

The growth in the COX-1 inhibitor market is driven by the rising prevalence of inflammatory disorders, advancements in drug delivery systems, and increasing consumer demand for effective pain management solutions. The expansion of pharmaceutical research in targeted anti-inflammatory therapies has led to the development of innovative COX-1 inhibitors with improved safety profiles.

End-use expansion is another critical driver, with applications in post-surgical pain management, cardiovascular disease prevention, and neuroinflammatory disorders. The increasing use of COX-1 inhibitors in veterinary medicine has also contributed to market growth. Additionally, collaborations between pharmaceutical companies and research institutions are accelerating the development of next-generation COX-1 inhibitors, ensuring continued advancements in anti-inflammatory drug therapy.

SCOPE OF STUDY:

The report analyzes the Cyclooxygenase 1 Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Selective COX-1 Inhibitor, Non-Selective COX-1 Inhibitor); Application (Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application, Other Applications); Distribution Channel (Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel, Retail Pharmacy Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals plc
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V. (now part of Viatris Inc.)
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cyclooxygenase 1 Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Inflammatory Disorders and Arthritis Driving Drug Demand
    • Increased R&D in Selective COX-1 Inhibition for Reduced GI Side Effects
    • Growing Adoption in Veterinary Medicine for Pain and Inflammation Management
    • Expansion of Geriatric Population Elevating Demand for Anti-Inflammatory Medications
    • Use in Cardiovascular Therapy as Antithrombotic Agents Supporting Market Uptake
    • Emerging Applications in Cancer Prevention and Adjunctive Oncology Therapies
    • Advancements in Drug Delivery Systems Enhancing Targeted COX-1 Inhibition
    • Increased Investment in Biosimilar and Generic Development Boosting Accessibility
    • Adoption in Combination Therapies for Broader Anti-Inflammatory Action
    • Shift Toward Non-Opioid Pain Management Approaches Accelerating Research
    • Growing Inclusion in OTC Analgesics and Pain Relief Products
    • Pharmaceutical Pipeline Expansion with New COX-1 Candidates in Trials
    • Patient Preference for Oral and Sustained-Release Formulations Supporting Innovation
    • Integration of AI in Drug Discovery Accelerating COX-1 Inhibitor Development
    • Surge in Hospital and Clinical Use for Postoperative and Acute Pain Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cyclooxygenase 1 Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cyclooxygenase 1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Selective COX-1 Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Selective COX-1 Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Selective COX-1 Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Selective COX-1 Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Selective COX-1 Inhibitor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Selective COX-1 Inhibitor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Inflammatory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Inflammatory Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Inflammatory Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Gastrointestinal Toxicity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Gastrointestinal Toxicity Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Gastrointestinal Toxicity Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Cancer Chemoprevention Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Cancer Chemoprevention Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Cancer Chemoprevention Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacy Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Online Pharmacy Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Retail Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Retail Pharmacy Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Retail Pharmacy Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • JAPAN
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • CHINA
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • EUROPE
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Cyclooxygenase 1 Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • FRANCE
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • GERMANY
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Cyclooxygenase 1 Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • INDIA
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Cyclooxygenase 1 Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Cyclooxygenase 1 Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030
  • AFRICA
    • Cyclooxygenase 1 Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Cyclooxygenase 1 Inhibitors by Type - Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Type - Percentage Breakdown of Value Sales for Selective COX-1 Inhibitor and Non-Selective COX-1 Inhibitor for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Cyclooxygenase 1 Inhibitors by Application - Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Application - Percentage Breakdown of Value Sales for Inflammatory Diseases Application, Gastrointestinal Toxicity Application, Cancer Chemoprevention Application and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Cyclooxygenase 1 Inhibitors by Distribution Channel - Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Cyclooxygenase 1 Inhibitors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channel, Online Pharmacy Distribution Channel and Retail Pharmacy Distribution Channel for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제